2. Traser Watches to make India
debut next year
Swiss Watch brand Traser, known for its permanent
illumination technology, is likely to enter India next
year in partnership with watch retail chain, Ethos.
Chandigarh-based Kamla Retail Ltd that runs 24
Ethos stores to sell fashion and luxury Swiss
watches is in the process of tying up with Traser to
become its exclusive retailer in India.
Traser watches come with its unique 'gaseous tritium
light' technology that makes the dials glow
permanently.
3. Nestle ups stake in Indian arm
Nestle, the world’s largest food company , has
increased its stake in its Indian arm by 0.8% and has
increased its stake in Nestle India to 62.76%.
In the long-term, there is a possibility that the
company could delist from Indian exchanges to
capture the full potential of the Indian growth.
Nestle’s holding in local arm is the highest among its
peers — Unilever holds 52% in Hindustan Unilever
and GlaxoSmithKline owns 43% in GSK Consumer
Healthcare India
4. Cadbury to start producing Kraft
Foods' Tang in India
Cadbury will start local manufacturing of parent Kraft
Foods' orange drink Tang.
It will also embark on a capacity expansion for its
confectionery products.
Earlier Tang was being imported from Thailand and
now will be produced at Kraft's Hyderabad plant.
Cadbury India came under the Kraft Foods fold after
the US-based firm acquired British candy maker,
Cadbury Plc for $19.6 billion.
5. Nissan to unveil diesel variant of
Micra in India
Nissan Motor India Limited will unveil the diesel
variant of its Micra compact hatchback car in
December second week.
India will be the first country to have the 1.5-litre K9K
diesel version of Micra hatchback with intelligent key,
immobilizer, a push-button engine start-stop system
and electric foldable mirror.
Nissan formed the 50:50 joint venture with French
automaker Renault to set up a manufacturing plant
at Oragadam near Chennai.
6. Centre bans anti-obesity drug
due to side effects
The government has banned manufacturing and sale
of anti-obesity medicine Sibutramine and its
combination drugs sold under various brands due to
side effects .
The Drug Controller General of India committee was
formed to look into the matter, after US-based Abbott
Laboratories withdrew its brand from the local
market.
Sibutramine is the third drug used for treating
diabetes and obesity that has been banned in India
in the past two years.